Search

Your search keyword '"Dugall, M."' showing total 484 results
Start Over Author "Dugall, M."
484 results on '"Dugall, M."'

5. Treatment of chronic venous insufficiency and prevention of economy class syndrome.

Author

Belcaro, G., primary, Cesarone, M. R., additional, Cornelli, U., additional, Rohdewald, P., additional, Ledda, A., additional, Renzo, A. di, additional, Stuard, S., additional, Cacchio, M., additional, Vinciguerra, G., additional, Gizzi, G., additional, Pellegrini, L., additional, Dugall, M., additional, Ricci, A., additional, Ruffini, I., additional, and Fano, F., additional

Published
2008
Full Text
View/download PDF

7. Management of Superficial Vein Thrombosis and Thrombophlebitis: Status and Expert Opinion Document

Author

Cesarone, M. R., Belcaro, G., Agus, G., Georgiev, M., Errichi, B. M., Marinucci, R., Errichi, S., Filippini, A., Pellegrini, L., Ledda, A., Vinciguerra, G., Ricci, A., Cipollone, G., Lania, M., Gizzi, G., Ippolito, E., Bavera, P., Fano, F., Dugall, M., Adovasio, R., Gallione, L., Del Boccio, G., Cornelli, U., Steigerwalt, R., Acerbi, G., Cacchio, M., Di Renzo, A., Hosoi, M., Stuard, S., Corsi, M., Di Ciano, L., Simeone, E., Collevecchio, G., Grossi, M. G., Di Giambattista, F., Carestia, F., and Zukowski, A.

Published
2007

8. Topical Heparin: New Observations

Author

Cesarone, M. R., Belcaro, G., Errichi, S., Cornelli, U., Pellegrini, L., Ruffini, I., Errichi, B. M., Ledda, A., Vinciguerra, G., Ricci, A., Gizzi, G., Ippolito, E., Fano, F., Dugall, M., Cacchio, M., Di Renzo, A., Hosoi, M., Grossi, M. G., Stuard, S., and Corsi, M.

Published
2007

18. Prevention of Edema in Long Flights with Pycnogenol®

Author

Cesarone, M. R., Belcaro, G., Rohdewald, P., Pellegrini, L., Ippolito, E., Scoccianti, M., Ricci, A., Dugall, M., Cacchio, M., Ruffini, I., Fano, F., Acerbi, G., Vinciguerra, M. G., Bavera, P., Di Renzo, A., Errichi, B. M., and Mucci, F.

Published
2005

26. Efficacy of tropical treatment with Aescin and essential phospholipids gel in a microcirculatory model of venous insufficiency

Author

Belcaro, G., Cesarone, M. R., and Dugall, M.

Subjects
Venous insufficiency -- Care and treatment, Phospholipids -- Dosage and administration, Phospholipids -- Evaluation, Health
Abstract

The effects of topical aescin and essential phospholipids gel (AEPL) in a histamine model of acute microangiopathy as compared to microangiopathy observed in chronic venous disease are evaluated. The fidings indicate that AEPL is effective and very active on the skin, in topical applications even at small dosages in a model of acute microangiopathy, comparable to venous hypersensitive microangiopathy and diabetic microangiopathy.

Published
2004

27. Microcirculatory efficacy of topical treatment with Aescin + essential phospholipids gel on transcutaneous PO2 in venous insufficiency

Author

Cesarone, M. R., Belcaro, G., Ippolito, E., Ricci, A., Ruffini, M., and Dugall, M.

Subjects
Microcirculation disorders -- Care and treatment, Venous insufficiency -- Care and treatment, Phospholipids -- Evaluation, Phospholipids -- Dosage and administration, Health
Abstract

The efficacy of the effects of Aescin and essential phospholipids (AEPL) gel on the microcirculation in subjects with chronic venous insufficiency, venous hypertension (CVH) and venous microangiopathy is evaluated. The studies on the considerations of transcutaneous PO2 indicate that the topical treatment with AEPL in areas of venous microangiopathy is beneficial for preventing ulceration, and improving the skin healing.

Published
2004

28. Microcirculatory efficacy of topical treatment with Aescin + essential phospholipids gel in venous insufficiency and hypertension: new clinical observations

Author

Belcaro, G., Cesarone, M. R., and Dugall, M.

Subjects
Venous insufficiency -- Care and treatment, Cookery for hypertensives -- Care and treatment, Hypertension -- Care and treatment, Phospholipids -- Dosage and administration, Phospholipids -- Research, Health
Abstract

The efficacy of the effects of Aescin and essential phospholipids (AEPL) gel on the microcirculation in subjects with chronic venous insufficiency, venous hypertension (CVH) and venous microangiopathy is investigated. The findings reveal that the topical treatment with AEPL in areas of venous microangiopathy is beneficial for preventing ulceration, and improving the skin healing processes.

Published
2004

29. Variations in plasma free radicals with topical Aescin + essential phospholipids gel in venous hypertension: new clinical data

Author

Ricci, A., Ruffini, I., Cesarone, M. R., Cornelli, U., Corsi, M., Belcaro, G., Ippolito, E., and Dugall, M.

Subjects
Cookery for hypertensives -- Care and treatment, Hypertension -- Care and treatment, Venous insufficiency -- Care and treatment, Phospholipids -- Dosage and administration, Phospholipids -- Research, Health
Abstract

A study is conducted to evaluate the effects of Aescin and essential phospholipids (AEPL) gel on plasma free radicals (PFRs). The conclusion states that evaluation of PFR is an important new physiologic parameter that can be associated with other noninvasive tests to study the microcirculation and its evolution as well as improvement with systemic or tropical medical treatment.

Published
2004

30. Foam-Sclerotherapy, Surgery, Sclerotherapy, and Combined Treatment for Varicose Veins: A 10-Year, Prospective, Randomized, Controlled, Trial (VEDICO* Trial)

Author

Belcaro, G., Cesarone, M. R., Di Renzo, A., Brandolini, R., Coen, L., Acerbi, G., Marelli, C., Errichi, B. M., Malouf, M., Myers, K., Christopoulos, D., Nicolaides, A., Geroulakos, G., Vasdekis, S., Simeone, E., Ricci, A., Ruffini, I., Stuard, S., Ippolito, E., Bavera, P., Georgiev, M., Corsi, M., Scoccianti, M., Cornelli, U., Caizzi, N., Dugall, M., Christopoulos, D., Veller, M., Venniker, R., Cazaubon, M., and Griffin, M.

Published
2003

33. Prevention of venous thrombosis in long-haul flights with Flite Tabs: the LONFLIT-Flite randomized, controlled trial

Author

Cesarone, M.R., Belcaro, G., Nicolaides, A.N., Ricci, A., Geroulakos, G., Ippolito, E., Brandolini, R., Vinciguerra, G., Dugall, M., Griffin, M., Ruffini, I., Acerbi, G, Corsi, M., Riordan, N.H., Stuard, S., Bavera, P., Di Renzo, A., Kenyon, J., and Errichi, B.M.

Subjects
Statistics, Edema -- Prevention, Dropsy -- Prevention, Thrombophlebitis -- Prevention, Health
Published
2003

38. Variations in plasma free radicals in patients with venous hypertension with HR (Paroven, Venoruton; O-([beta]-hydroxyethyl)-rutosides): A clinical, prospective, placebo-controlled, randomized trial

Author

Cesarone, M.R., Incandela, L., DeSanctis, M.T., Belcaro, G., Dugall, M., and Acerbi, G.

Subjects
Free radicals (Chemistry) -- Physiological aspects, Venous pressure -- Care and treatment, Hypertension -- Care and treatment, Venous insufficiency -- Care and treatment, Health
Published
2002

41. PGE1 Treatment of Severe Intermittent Claudication (Short-Term Versus Long-Term, Associated with Exercise): Efficacy and Costs in a 20-Week, Randomized Trial

Author

Belcaro, G., Nicolaides, A. N., Agus, G., Cesarone, M. R., Geroulakos, G., Pellegrini, L., De Sanctis, M. T., Incandela, L., Ricci, A., Mondani, P., De Angelis, R., Ippolito, E., Barsotti, A., Vasdekis, S., Ledda, A., Christopoulos, D., Errichi, B. M., Helmis, H., Cornelli, U., Ramaswami, G., Dugall, M., Bucci, M., Martines, G., Ferrari, P. G., Corsi, M., Di Francescantonio, D., Pomante, P., Mezzanotte, L., Petrucci, M., and Ciccarelli, R.

Published
2000

42. Nomograms Used to Define the Short-Term Treatment with PGE1 in Patients with Intermittent Claudication and Critical Ischemia. The ORACL.E (Occlusion Revascularization in the Atherosclerotic Critical Limb) Study Group. The European Study

Author

Belcaro, G., Nicolaides, A. N., Cipollone, G., Laurora, G., Incandela, L., Cazaubon, M., Barsotti, A., Ledda, A., Errichi, B. M., Cornelli, U., Dugall, M., Corsi, M., Mezzanotte, L., Geroulakos, G., Fisher, C., Szendro, G., Simeone, E., Cesarone, M. R., Bucci, M., Agus, G., De Sanctis, M. T., Ricci, A., Ippolito, E., Vasdekis, S., Christopoulos, D., Helmis, H., Ramaswami, G., Ferrari, P. G., Pomante, P., Petrucci, M., Veller, M., Venniker, R., Iacobitti, P., Martines, G., and Ciccarelli, R.

Published
2000

44. Highly standardized cranberry extract supplementation (Anthocran®) as prophylaxis in young healthy subjects with recurrent urinary tract infections

Author

Ledda, A., Belcaro, G., Dugall, M., Riva, A., Togni, S., Eggenhoffner, R., and Luca Giacomelli

Subjects
Male, Vaccinium macrocarpon, Adolescent, Plant Extracts, Female, Humans, Phytotherapy, Urinary Tract Infections
Abstract

Several studies have investigated the role of cranberry extract in the prevention of recurrent urinary tract infections (UTIs), on different selected subpopulations at increased risk of UTI. In this registry, we tested the prophylactic effects of an oral supplementation containing a highly standardized cranberry extract (Anthocran®) in young subjects with a previous history of recurrent UTIs, over a 2-months follow-up.36 otherwise healthy subjects in juvenile age (between 12 and 18 years of age) suffering by recurrent UTIs were enrolled. Participants received either a standard management (SM) (control group, n=17) or SM associated with an oral daily supplementation (supplementation group, n=19). Oral supplementation consisted in one capsule containing 120 mg of cranberry extract (Anthocran®), standardized to 36 mg proanthocyanidins, for 60 days. The effectiveness in the prevention of UTIs was determined by: the number of UTIs evaluated two months before the inclusion in the registry and during the supplementation period; the number of symptom-free subjects during the registry period. Safety considerations and measurement of adherence to treatment were also performed.The two groups were comparable for age, gender distribution, the days of follow-up and also for the number of UTIs before inclusion. The mean number of UTIs observed during the registry in the supplemented group (0.31±0.2) was significantly lower compared to the control group (2.3±1.3) and to the mean number of UTIs assessed before inclusion (1.74±1.1) (p-value = 0.0001 for both). Moreover, 63.1% of supplemented subjects was symptom-free during the registry period, whereas 23.5% subjects were asymptomatic in the control group (p-value0.05).This registry supplement study provides compelling evidence on the efficacy of an oral supplementation, based on a highly standardized cranberry extract (Anthocran®), as prophylaxis in young healthy subjects suffering by recurrent UTIs.

Published
2017

45. Efficacy of topical treatment with Aescin + essential phospholipids gel on capillary fragility

Author

Cesarone, M. R., Ricci, A., Renzo, A. Di, Belcaro, G., and Dugall, M.

Subjects
Capillarity -- Diagnosis, Edema -- Diagnosis, Dropsy -- Diagnosis, Phospholipids -- Dosage and administration, Phospholipids -- Evaluation, Health
Abstract

A study evaluating the local capillary fragility with the vacuum suction chamber (VSC) in patients with chronic venous hypertension due to chronic venous disease is presented. The observations of VSC applied in different skin areas showed that aescin and essential phospholipids gel in local treatment detects edema and produces a decreased risk for venous ulcerations.

Published
2004

46. Efficacy of topical treatment with aescin and essential phospholipids gel in venous insufficiency and hypertension

Author

Ruffini, I., Belcaro, G., Cesarone, M. R., and Dugall, M.

Subjects
Cookery for hypertensives -- Care and treatment, Hypertension -- Care and treatment, Venous insufficiency -- Care and treatment, Phospholipids -- Dosage and administration, Phospholipids -- Evaluation, Health
Abstract

A study is conducted to examine the efficacy of an aescin and essential phospholipids (AEPL) gel on the microcirculation measuring treanscutaneous skin PO2 and PCO2 subjects with chronic venous insufficiency, venous hypertension (CVH), and venous microangiopathy. The results reveal that the local treatment with AEPL in the areas of microangiopathy is effective in improving skin perfusion and nutrition and prevents venous ulcerations.

Published
2004

47. A novel lecithin based delivery form of Boswellic acids (Casperome®) for the management of osteo-muscular pain: a registry study in young rugby players

Author

Franceschi, F., Togni, S., Belcaro, G., Dugall, M., Luzzi, R., Ledda, A., Pellegrini, L., Eggenhoffner, R., and Luca Giacomelli

Subjects
Adult, Male, Adolescent, Plant Extracts, Football, Triterpenes, Young Adult, Boswellia, Humans, Knee, Lecithins, Pain Management, Registries
Abstract

Several experimental studies and clinical trials support the potential of Boswellia serrata extracts (BSE) for the treatment of various inflammatory diseases. The aim of this registry study was to assess the safety and the efficacy of a novel lecithin-based delivery form of Boswellia serrata extract (Casperome®) in the supportive management of osteo-muscular pain.52 healthy young rugby players with acute knee pain and inflammation were recruited. Informed participants freely decided to follow either a standard management (SM) to control joint pain (control group = 27) or SM associated with oral daily supplementation with Casperome® (supplement group =25). Parameters associated with osteo-muscular pain and inflammation, and measurements of joint health and functions were assessed at the inclusion and after a 4-week supplementation.A significant beneficial effect of Casperome® vs SM alone was observed for all the parameters evaluated, namely: local pain on effort; pain-free walking distance (treadmill test); minimal joint effusion; structural damage (joint, tendons, muscles) and intramuscular hematomas; thermal imaging of the anterior knee; Visual Analog Scale for Pain (VAS Pain); need for concomitant drugs and medical attention; measurement of inflammatory biomarkers.Our registry study suggests that Casperome® supplementation could represent an effective and safe, integrated approach for the treatment of osteo-muscular pain and inflammation.

Published
2016

48. Managing ulcerative colitis in remission phase: usefulness of Casperome®, an innovative lecithin-based delivery system of Boswellia serrata extract

Author

Pellegrini, L., Milano, E., Franceschi, F., Belcaro, G., Gizzi, G., Feragalli, B., Dugall, M., Luzzi, R., Togni, S., Roberto Eggenhoffner, and Giacomelli, L.

Subjects
Drug Delivery Systems, Plant Extracts, Lecithins, Remission Induction, Colitis, Ulcerative, Humans, Boswellia, Ulcerative, Colitis
Abstract

Boswellia serrata extracts (BSE) have been traditionally used for the treatment of several inflammatory diseases. The aim of this study was to evaluate the efficacy of a novel delivery form of BSE (Casperome®) in Ulcerative Colitis (UC) during minimally symptomatic remission phase.In this open-label, observational, registry study, informed participants with UC in remission phase (n = 43) freely decided to receive the oral daily Casperome® supplementation (n = 22) or no supplementation (n = 21) for 4 weeks. Several parameters associated with minimally symptomatic UC in remission were evaluated at the inclusion and the end of the study.A significant beneficial effect of Casperome® was observed for all the parameters evaluated, namely: diffuse intestinal pain, evident and occult blood in stools, bowel movements and cramps, watery stools, malaise, anemia, rectal involvement, number of white blood cells as well as need for concomitant drugs and medical attention. Faecal concentration of calprotectin, a marker of bowel inflammation, resulted ameliorated in Casperome® supplemented patients.Our study showed that Casperome® supplementation attenuates symptoms associated with mild UC in remission, reducing the use of drugs and medical consultations. Therefore, our study suggests that Casperome® supplementation could represent a promising alternative approach to manage minimally symptomatic UC and maintain the remission phase.

Published
2016

49. Management of Varicose Veins and Chronic Venous Insufficiency in a Comparative Registry with Nine Venoactive Products in Comparison with Stockings

Author

Dugall, M., primary, Luzzi, R., primary, Corsi, M., primary, Ledda, A., primary, Ricci, A., primary, Pellegrini, L., primary, Cesarone, M., primary, Hosoi, M., primary, Errichi, B.M., primary, Cornelli, U., primary, Cotellese, R., primary, Agus, G., primary, Feragalli, B., primary, and Belcaro, G., additional

Published
2016
Full Text
View/download PDF

50. Interaction study between antiplatelet agents, anticoagulants, thyroid replacement therapy and a bioavailable formulation of curcumin (Meriva®).

Author

HU, S., BELCARO, G., DUGALL, M., PETERZAN, P., HOSOI, M., LEDDA, A., RIVA, A., GIACOMELLI, L., TOGNI, S., EGGENHOFFNER, R., and COTELLESE, R.

Abstract

OBJECTIVE: The objective of this clinical study is to evaluate possible interactions between antiplatelet agents, anticoagulants, thyroid hormone replacement therapy and a formulation of curcumin (Meriva®) that resulted effective for the complementary treatment of osteoarthritis. PATIENTS AND METHODS: Interaction between antiplatelet agents and Meriva® was evaluated by measuring anti-platelet activity with the in-vivo bleeding-time (BT) in patients assuming acetylsalicylic acid or ticlopidine or clopidogrel from at least 2 years. The BT was evaluated before and after 10 days of supplementation with Meriva®. The interaction between anticoagulants and Meriva® was evaluated in patients using warfarin or dabigatran for previous venous thrombosis. The INR level was evaluated before and after 10 days of supplementation with the curcumin formulation. Thyroid function tests in hypothyroid patients using LT4 replacement therapy (Eutirox®) were evaluated before and after 15 days of supplementation with Meriva®. Similarly, levels of glycemia and glycated hemoglobin were evaluated in diabetic patients in treatment with metformin, before and after 10 days of supplementation with the studied product. RESULTS: After 10 days of supplementation with Meriva® the average BT value was not significantly different for patients assuming acetylsalicylic acid, ticlopidine or clopidogrel at standard dosages. Similarly, after 10 days of Meriva® treatment, the INR level in the two groups of patients assuming warfarin or dabigatran was not statistically different from that observed at baseline. In the analyzed patients assuming LT4 or metformin, no interactions between the therapy and Meriva® were observed. CONCLUSIONS: Results from this non-interaction clinical study suggest that Meriva® does not interfere with the antiplatelet activity of the most common antiplatelet agents nor alters the INR values in stable patients assuming warfarin or dabigatran. Similarly, dosages of LT4 or metformin do not need to be adjusted in case of complementary treatment with Meriva®. [ABSTRACT FROM AUTHOR]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results